Clinical Trials
YELLOW II Study
The Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering study assessed changes in plaque morphology by IVUS in patients receiving high-intensity statin therapy.
Design: Prospective, single-arm
Patients: 85
Center: Single
Country: United States
Results: Minimal fibrous cap thickness increased from 100.9 µm at baseline to 108.6 µm at 12 weeks (P < .001). Cholesterol efflux capacity increased from 0.81 at baseline to 0.84 at 12 weeks (P = .003). Thin-cap fibroatheroma prevalence fell from 20% at baseline to 7.1% at 12 weeks (P = .003). Changes in fibrous cap thickness were independently associated with increased cholesterol efflux capacity (beta, 0.3; 95% CI, 0.07-0.54; P = .01). Unique clusters of genes were associated with positive changes in fibrous cap thickness and cholesterol efflux capacity.
Original Publications:
Kini AS, et al. J Am Coll Cardiol. 2016;doi:10.1016/j.jacc.2016.10.029.